tyramine has been researched along with Idiopathic Parkinson Disease in 51 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Rasagiline mesylate is a novel irreversible selective monoamine oxidase type B inhibitor for Parkinson disease that may have a low risk of interaction with dietary tyramine because of its selectivity." | 9.13 | Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. ( Salzman, P; Schwid, SR; White, WB, 2008) |
| "Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa." | 8.88 | The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? ( Chen, JJ; Wilkinson, JR, 2012) |
| " Rasagiline mesylate is a novel irreversible selective monoamine oxidase type B inhibitor for Parkinson disease that may have a low risk of interaction with dietary tyramine because of its selectivity." | 5.13 | Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. ( Salzman, P; Schwid, SR; White, WB, 2008) |
| "Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa." | 4.88 | The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? ( Chen, JJ; Wilkinson, JR, 2012) |
| " Patients with PD+NOH had normal bradycardia responses to edrophonium and normal epinephrine responses to glucagon." | 3.74 | Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. ( Goldstein, DS; Holmes, C; Imrich, R; Pechnik, S; Sharabi, Y, 2008) |
| "This randomized, double-blind, placebo-, comparator (selegiline 10 mg/day)-, and positive (phenelzine 30 mg/day)-controlled study investigated the pressor response to oral tyramine under fasting conditions after the administration of safinamide at therapeutic (100 mg/day) and supratherapeutic (350 mg/day) dosing regimens in healthy volunteers for the purpose of assessing the need for dietary restrictions." | 2.77 | The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. ( Astruc, B; Johne, A; Kovar, A; Krösser, S; Kupas, K; Marquet, A; Patat, A, 2012) |
| "Early diagnosis of Parkinson's disease (PD) remains a challenge to date." | 1.51 | Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson's Disease Patients. ( Baraldi, E; D'Andrea, G; Giordano, G; Gucciardi, A; Leon, A; Pizzolato, G; Stocchero, M, 2019) |
| "Diseases characterized by neurogenic orthostatic hypotension (NOH), such as Parkinson disease (PD) and pure autonomic failure (PAF), are associated with cardiac sympathetic denervation, as reflected by low myocardial concentrations of 6-[(18)F]fluorodopamine-derived radioactivity." | 1.35 | Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension. ( Bentho, O; Eldadah, BA; Goldstein, DS; Grossman, E; Holmes, C; Imrich, R; Pechnik, S; Sharabi, Y, 2009) |
| "There is denervation supersensitivity in PD patients that is, however, insufficient to shift the dose-response curve to the left." | 1.35 | Systemic postganglionic adrenergic studies do not distinguish Parkinson's disease from multiple system atrophy. ( Lipp, A; Low, PA; Sandroni, P, 2009) |
| "Parkinson's disease is characterized by the loss of dopamine (DA) neurons, which leads to overactivity of the surviving DA neurons and an increase in neurotransmitter release and turnover." | 1.31 | Oxidative stress, mitochondrial respiration, and Parkinson's disease. ( Cohen, G, 2000) |
| "Although the selective monoamine oxidase (MAO) B inhibitor, (-)deprenyl, has been shown to be free from the "cheese effect" in man after tyramine challenge, the reason for this is far from clear: it may well be independent of the selective inhibitory action of the drug, for during chronic administration there is some evidence to suggest that both A and B forms of the enzyme are equally inhibited." | 1.26 | Absence of "cheese effect" during deprenyl therapy: some recent studies. ( Ashford, A; Glover, V; Sandler, M; Stern, GM, 1978) |
| "Levodopa induced an increase of about 400 fold in urinary DA; DOPAC was increased about 300 fold, 3-MT only about 70 fold, but HVA about 300 fold." | 1.25 | Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. ( Rinne, UK; Siirtola, T; Sonninen, V, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (47.06) | 18.7374 |
| 1990's | 7 (13.73) | 18.2507 |
| 2000's | 11 (21.57) | 29.6817 |
| 2010's | 6 (11.76) | 24.3611 |
| 2020's | 3 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Distinto, S | 1 |
| Yáñez, M | 1 |
| Alcaro, S | 1 |
| Cardia, MC | 1 |
| Gaspari, M | 1 |
| Sanna, ML | 1 |
| Meleddu, R | 1 |
| Ortuso, F | 1 |
| Kirchmair, J | 1 |
| Markt, P | 1 |
| Bolasco, A | 1 |
| Wolber, G | 1 |
| Secci, D | 1 |
| Maccioni, E | 1 |
| Albillos, SM | 1 |
| Montero, O | 1 |
| Calvo, S | 1 |
| Solano-Vila, B | 1 |
| Trejo, JM | 1 |
| Cubo, E | 1 |
| Su, Y | 1 |
| Liu, Y | 1 |
| He, D | 1 |
| Hu, G | 1 |
| Wang, H | 1 |
| Ye, B | 1 |
| He, Y | 1 |
| Gao, X | 1 |
| Liu, D | 1 |
| Meiring, L | 1 |
| Petzer, JP | 1 |
| Legoabe, LJ | 1 |
| Petzer, A | 1 |
| D'Andrea, G | 1 |
| Pizzolato, G | 1 |
| Gucciardi, A | 1 |
| Stocchero, M | 1 |
| Giordano, G | 1 |
| Baraldi, E | 1 |
| Leon, A | 1 |
| Imrich, R | 3 |
| Eldadah, BA | 2 |
| Bentho, O | 2 |
| Pechnik, S | 3 |
| Sharabi, Y | 3 |
| Holmes, C | 3 |
| Grossman, E | 1 |
| Goldstein, DS | 3 |
| White, WB | 2 |
| Salzman, P | 1 |
| Schwid, SR | 2 |
| Isaacson, SH | 1 |
| Lipp, A | 1 |
| Sandroni, P | 1 |
| Low, PA | 1 |
| Goren, T | 1 |
| Adar, L | 1 |
| Sasson, N | 1 |
| Weiss, YM | 1 |
| Chen, JJ | 1 |
| Wilkinson, JR | 1 |
| Marquet, A | 1 |
| Kupas, K | 1 |
| Johne, A | 1 |
| Astruc, B | 1 |
| Patat, A | 1 |
| Krösser, S | 1 |
| Kovar, A | 1 |
| Clarke, A | 1 |
| Johnson, ES | 1 |
| Mallard, N | 1 |
| Corn, TH | 1 |
| Johnston, A | 1 |
| Boyce, M | 1 |
| Warrington, S | 1 |
| MacMahon, DG | 1 |
| Youdim, MB | 4 |
| Riederer, PF | 1 |
| Gluck, MR | 1 |
| Zeevalk, GD | 1 |
| deMarcaida, JA | 1 |
| Blindauer, K | 1 |
| Fahn, S | 2 |
| Kieburtz, K | 1 |
| Stern, M | 1 |
| Shoulson, I | 1 |
| Drozak, J | 1 |
| Kozłowski, M | 1 |
| Boulton, AA | 5 |
| Pollitt, RJ | 1 |
| Majer, JR | 1 |
| Sandler, M | 6 |
| Da Prada, M | 1 |
| Keller, HH | 1 |
| Pieri, L | 1 |
| Kettler, R | 1 |
| Haefely, WE | 1 |
| Karoum, F | 1 |
| Chuang, LW | 1 |
| Eisler, T | 1 |
| Calne, DB | 1 |
| Liebowitz, MR | 1 |
| Quitkin, FM | 1 |
| Klein, DF | 1 |
| Wyatt, RJ | 1 |
| Andrew, R | 1 |
| Watson, DG | 1 |
| Best, SA | 1 |
| Midgley, JM | 1 |
| Wenlong, H | 1 |
| Petty, RK | 1 |
| Riederer, P | 1 |
| Gargalidis-Moudanos, C | 1 |
| Pizzinat, N | 1 |
| Javoy-Agid, F | 1 |
| Remaury, A | 1 |
| Parini, A | 1 |
| Cohen, G | 3 |
| Farooqui, R | 1 |
| Kesler, N | 2 |
| Chouinard, S | 1 |
| Volz, HP | 1 |
| Gleiter, CH | 1 |
| Dalmaz, Y | 1 |
| Peyrin, L | 1 |
| Elsworth, JD | 1 |
| Glover, V | 2 |
| Reynolds, GP | 1 |
| Lees, AJ | 2 |
| Phuapradit, P | 1 |
| Shaw, KM | 1 |
| Stern, GM | 4 |
| Kumar, P | 1 |
| Knoll, J | 1 |
| Ashford, A | 1 |
| Bronaugh, RL | 1 |
| Hattox, SE | 1 |
| Hoehn, MM | 1 |
| Murphy, RC | 1 |
| Rutledge, CO | 1 |
| Siirtola, T | 1 |
| Sonninen, V | 1 |
| Rinne, UK | 1 |
| Finberg, JP | 1 |
| Ruthven, CR | 2 |
| Goodwin, BL | 2 |
| Hunter, KR | 1 |
| Godwin-Austen, RB | 1 |
| Lind, NA | 1 |
| Turner, P | 1 |
| Marjerrison, GL | 1 |
| Wu, PH | 1 |
| Boulton, A | 1 |
| Marjerrison, L | 1 |
| Majer, D | 1 |
| Marjerrison, G | 2 |
| Rajput, AH | 1 |
| Goodall, M | 1 |
| Alton, H | 1 |
| Barbeau, A | 1 |
| Rajput, A | 1 |
| Smith, I | 1 |
| Kellow, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identifying the Pathophysiology of Neurogenic Orthostatic Hypotension and the Effects of Melatonin on Reducing Supine Hypertension in Peripherally Intact Versus Denervated Post-ganglionic Sympathetic Nerves[NCT02963181] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-03-01 | Terminated (stopped due to PI leaving) | ||
| Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study[NCT03843944] | Phase 4 | 20 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for tyramine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Topics: Antiparkinson Agents; Brain; Dietary Proteins; Dose-Response Relationship, Drug; Food-Drug Interacti | 2012 |
A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Basal Ganglia; Cheese; Child; Child, Preschool; Dopam | 2004 |
[Monoamine oxidase as a target for drug action].
Topics: Alzheimer Disease; Animals; Antidepressive Agents; Antiparkinson Agents; Depression; Humans; Monoami | 2006 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bro | 1984 |
Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Catechol O-Methyltransferase; Catechol O-Met | 1993 |
Monoamine oxidase inhibitors. A perspective on their use in the elderly.
Topics: Aged; Alzheimer Disease; Depression; Food-Drug Interactions; Humans; Monoamine Oxidase; Monoamine Ox | 1998 |
On the dual nature of monoamine oxidase.
Topics: Animals; Antidepressive Agents; Binding Sites; Brain; Catecholamines; Clorgyline; Dose-Response Rela | 1978 |
Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Topics: Animals; Brain; Dopamine; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase; Parkinson | 1986 |
6 trials available for tyramine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
Topics: Aged; Antihypertensive Agents; Antiparkinson Agents; Blood Pressure; Blood Pressure Monitoring, Ambu | 2008 |
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Topics: Adult; Aged; Algorithms; Contraindications; Diet; Dose-Response Relationship, Drug; Double-Blind Met | 2010 |
The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial.
Topics: Administration, Oral; Adult; Aged; Alanine; Benzylamines; Blood Pressure; Dose-Response Relationship | 2012 |
A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
Topics: Administration, Oral; Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy | 2003 |
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Blood Pressure; Dose-Response Relationship, Drug; | 2006 |
Experience with tranylcypromine in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Depression; Erectile Dysfunction; Female; Foll | 1998 |
37 other studies available for tyramine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.
Topics: Binding Sites; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dyn | 2012 |
Plasma acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol in Parkinson's disease and essential tremor. A case control biomarker study.
Topics: Aged; Bilirubin; Biomarkers; Carnitine; Case-Control Studies; Cognition; Cortodoxone; Diagnosis, Dif | 2021 |
Hordenine inhibits neuroinflammation and exerts neuroprotective effects via inhibiting NF-κB and MAPK signaling pathways in vivo and in vitro.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Lipopolysaccharides; MAP Kinase Signaling System; Micr | 2022 |
The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Propy | 2022 |
Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson's Disease Patients.
Topics: Adult; Aged; Biogenic Amines; Biomarkers; Cross-Sectional Studies; Disease Progression; Early Diagno | 2019 |
Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension.
Topics: Adrenergic beta-Agonists; Aged; Autonomic Nervous System Diseases; Blood Pressure; Dopamine; Female; | 2009 |
Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.
Topics: Aged; Blood Pressure; Bradycardia; Cholinesterase Inhibitors; Edrophonium; Epinephrine; Female; Gluc | 2008 |
Selective MAO-B inhibitors have low potential for the tyramine effect.
Topics: Blood Pressure; Heart Rate; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Tyramin | 2010 |
Attenuated pre-ejection period response to tyramine in patients with cardiac sympathetic denervation.
Topics: Aged; Autonomic Nervous System Diseases; Female; Heart; Hemodynamics; Humans; Male; Middle Aged; Par | 2008 |
Systemic postganglionic adrenergic studies do not distinguish Parkinson's disease from multiple system atrophy.
Topics: Adrenergic Agonists; Aged; Analysis of Variance; Baroreflex; Blood Pressure; Cohort Studies; Diagnos | 2009 |
Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Cell Respiration; Dopamine | 2004 |
Identity of a urinary "pink spot" in schizophrenia and Parkinson's disease.
Topics: Chromatography, Paper; Humans; Infrared Rays; Parkinson Disease; Phenethylamines; Schizophrenia; Spe | 1967 |
Monoamine oxidase inhibitors and their pharmacological significance.
Topics: Animals; Antidepressive Agents; Brain; Clorgyline; Humans; Monoamine Oxidase; Monoamine Oxidase Inhi | 1983 |
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Co | 1982 |
The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls.
Topics: Biogenic Monoamines; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Hydroxydopamines; Levod | 1993 |
I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Brain; Cerebral Cortex; Female; Humans; Idazoxan; Imidazoline Receptors; Ma | 1997 |
Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow.
Topics: Animals; Benzylamines; Brain; Dopamine; Electron Transport; Glutathione; Glutathione Disulfide; Huma | 1997 |
Monoamine oxidase and mitochondrial respiration.
Topics: Animals; Disulfides; Electron Transport; Electron Transport Complex I; Glutathione; Hydrogen Peroxid | 1999 |
Oxidative stress, mitochondrial respiration, and Parkinson's disease.
Topics: Animals; Brain; Dopamine; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidative S | 2000 |
Specific ion-exchange chromatography and fluorimetric assay for urinary 3-O-methyldopamine.
Topics: Adrenal Gland Neoplasms; Animals; Chromatography, Ion Exchange; Dogs; Dopamine; Humans; Hydrogen-Ion | 1976 |
Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.
Topics: Adult; Aged; Blood Platelets; Cheese; Female; Humans; Hypertension; Intestinal Mucosa; Male; Middle | 1978 |
Absence of "cheese effect" during deprenyl therapy: some recent studies.
Topics: Amphetamines; Animals; Blood Pressure; Humans; Intestines; Monoamine Oxidase; Parkinson Disease; Phe | 1978 |
Recent observations on the clinical pharmacology of (-)deprenyl.
Topics: Adult; Aged; Blood Pressure; Drug Therapy, Combination; Heart Rate; Humans; Levodopa; Middle Aged; P | 1978 |
The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of Parkinsonian patients.
Topics: Administration, Oral; Aged; Chromatography, Gas; Chromatography, High Pressure Liquid; Chromatograph | 1975 |
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Benserazide; Biogenic Amines; Dopamine; Female; Homovanillic Acid; H | 1975 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Hu | 1987 |
Variation of levodopa metabolism with gastrointestinal absorption site.
Topics: Administration, Oral; Aged; Animals; Biotransformation; Catechols; Dihydroxyphenylalanine; Dogs; Duo | 1974 |
Mydriatic responses to sympathomimetic amines in patients treated with L-dopa.
Topics: Adrenergic alpha-Antagonists; Dihydroxyphenylalanine; Humans; Hypotension; Mydriatics; Norepinephrin | 1969 |
Effect of L-dopa therapy on urinary p-tyramine excretion and EEG changes in Parkinson's disease.
Topics: Brain; Carbon Isotopes; Dihydroxyphenylalanine; Electroencephalography; Humans; Parkinson Disease; P | 1972 |
Effect of L-DOPA on the synthesis and excretion of tyramine.
Topics: Animals; Brain Stem; Caudate Nucleus; Cerebellum; Dopamine; Humans; Hypothalamus; Levodopa; Octopami | 1974 |
Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man.
Topics: Brain Chemistry; Chromatography; Dihydroxyphenylalanine; Dopamine; Humans; Intestines; Parkinson Dis | 1971 |
[Excretion, metabolism and central distribution of non-catecholic primary amines].
Topics: Animals; Brain; Humans; Octopamine; Parkinson Disease; Phenethylamines; Phenylacetates; Rats; Schizo | 1971 |
EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease.
Topics: Brain; Carbon Isotopes; Creatinine; Dihydroxyphenylalanine; Electroencephalography; Humans; Parkinso | 1972 |
Dopamine (3-hydroxytyramine) metabolism in parkinsonism.
Topics: Adult; Aged; Alcohols; Benzoates; Carbon Isotopes; Dopamine; Epinephrine; Humans; Male; Mandelic Aci | 1969 |
Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.
Topics: Administration, Oral; Animals; Dihydroxyphenylalanine; Haloperidol; Humans; Movement Disorders; Musc | 1970 |
Dopa therapy in parkinsonism effects on the EEG and amine metabolism.
Topics: Carbon Isotopes; Dihydroxyphenylalanine; Electroencephalography; Humans; Parkinson Disease; Tyramine | 1971 |
Aromatic amines and Parkinson's disease.
Topics: Chemistry, Clinical; Chromatography, Paper; Creatinine; Dopamine; Fluorometry; Humans; Parkinson Dis | 1969 |